Screener
Immunovant, Inc. IMVT Debt-to-equity
Debt-to-equity at other companies
Other financials
Where this comes from
Calculated from Immunovant, Inc.’s reported figures.
Based on the most recent quarter.
The source filing: Immunovant, Inc.’s 10-K, filed May 20, 2026. Open the filing →
- Filed
- May 20, 2026, 7:28 AM EDT
- Fiscal year
- FY2026
- Accession
- 0001764013-26-000064
FAQ
- What is Immunovant, Inc.'s debt-to-equity?
- Immunovant, Inc. (IMVT) reported debt-to-equity of 0× in Q1 2026.
- How has Immunovant, Inc.'s debt-to-equity changed year-over-year?
- Immunovant, Inc.'s debt-to-equity decreased by 0.0% year-over-year, from 0× to 0×.
- What is the long-term trend for Immunovant, Inc.'s debt-to-equity?
- Over 5 years (2021 to 2026), Immunovant, Inc.'s debt-to-equity has grown at a -59.1% compound annual growth rate (CAGR), from 0× to 0×.
- What does debt-to-equity mean?
- Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.
Ask your AI about Immunovant, Inc.'s debt-to-equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude